BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24312671)

  • 1. Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study.
    Kim S; Park YM
    PLoS One; 2013; 8(12):e82749. PubMed ID: 24312671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Prolactin Levels in Patients with Major Depressive Disorder Receiving Selective Serotonin-Reuptake Inhibitor Monotherapy for 3 Months: A Prospective Study.
    Park YM
    Psychiatry Investig; 2017 May; 14(3):368-371. PubMed ID: 28539956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine.
    Papakostas GI; Miller KK; Petersen T; Sklarsky KG; Hilliker SE; Klibanski A; Fava M
    J Clin Psychiatry; 2006 Jun; 67(6):952-7. PubMed ID: 16848655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.
    Masiran R; Sidi H; Mohamed Z; Mohd Nazree NE; Nik Jaafar NR; Midin M; Das S; Mohamed Saini S
    J Sex Med; 2014 Apr; 11(4):1047-1055. PubMed ID: 24533444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: A preliminary study.
    Park YM; Lee SH; Lee BH; Lee KY; Lee KS; Kang SG; Lee HY; Kim W
    Psychiatry Res; 2016 May; 239():184-9. PubMed ID: 27010188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.
    Leuchter AF; Lesser IM; Trivedi MH; Rush AJ; Morris DW; Warden D; Fava M; Wisniewski SR; Luther JF; Perales M; Gaynes BN; Stewart JW
    J Psychiatr Pract; 2008 Sep; 14(5):271-80. PubMed ID: 18832958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
    Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
    Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 9. Importance of macroprolactinemia in hyperprolactinemia.
    Kasum M; Pavičić-Baldani D; Stanić P; Orešković S; Sarić JM; Blajić J; Juras J
    Eur J Obstet Gynecol Reprod Biol; 2014 Dec; 183():28-32. PubMed ID: 25461348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder.
    Yoshimura R; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Atake K; Nakamura J
    Hum Psychopharmacol; 2013 Sep; 28(5):466-70. PubMed ID: 23813968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder - an experimental medicine blinded controlled trial.
    Knorr UB
    Dan Med J; 2012 Apr; 59(4):B4426. PubMed ID: 22459724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escitalopram: a review of its use in the management of major depressive disorder in adults.
    Garnock-Jones KP; McCormack PL
    CNS Drugs; 2010 Sep; 24(9):769-96. PubMed ID: 20806989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diminished functional properties of T regulatory cells in major depressive disorder: The influence of selective serotonin reuptake inhibitor.
    Jahangard L; Behzad M
    J Neuroimmunol; 2020 Jul; 344():577250. PubMed ID: 32344162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life.
    Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A
    J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder.
    Varigonda AL; Jakubovski E; Taylor MJ; Freemantle N; Coughlin C; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):557-64. PubMed ID: 26088660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Galactorrhoea and the use of selective serotonin reuptake inhibitors].
    Wessels-van Middendorp AM; Timmerman L
    Tijdschr Psychiatr; 2006; 48(3):229-34. PubMed ID: 16956087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between macroprolactin levels and vitamin D status in premenopausal women with macroprolactinemia: a pilot study.
    Krysiak R; Kowalska B; Szkróbka W; Okopień B
    Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):446-50. PubMed ID: 26179930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and reproductive manifestations of macroprolactinemia.
    Kalsi AK; Halder A; Jain M; Chaturvedi PK; Sharma JB
    Endocrine; 2019 Feb; 63(2):332-340. PubMed ID: 30269265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.